RSS   Newsletter   Contact   Advertise with us

Adial Pharmaceuticals appoints Alex Lugovoy as head of strategy

Christian Fernsby | Charlottesville, Va., USA | April 12, 2019
Alex LugovoyAdial Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Alex Lugovoy as head of strategy.
Mr. Lugovoy has almost 20 years of experience working in the pharmaceutical and biotechnology industries.

His management consulting and operational experience spans portfolio strategy, licensing, marketing, sales, medical, and research and development.

Prior to founding Dobrin Consulting, an addiction-focused consulting firm, Mr. Lugovoy started and led the Business Development, Strategy and MandA department at Reckitt Benckiser Pharmaceuticals (now Indivior), a leading global addiction pharmaceutical company.

During his tenure, he was responsible for overseeing product launch, lifecycle management strategy and execution, and worked to build a full product pipeline through licensing and partnerships with the leading addiction and CNS pharmaceutical companies.

Mr. Lugovoy joined Reckitt Benckiser Pharmaceuticals directly from Campbell Alliance, a leading healthcare management consulting company.

At Campbell Alliance, he led business development and brand management.

Previously, Mr. Lugovoy was a director at Columbia Science and Technology Ventures where he oversaw the development of five early-stage pharmaceutical/biotech companies, and he also worked as a sales and marketing professional at Eli Lilly where he helped launch Cymbalta.

He has an M.B.A. from Columbia University, and a B.A. in Neuroscience from Colgate University where he graduated magna cum laude, Phi Beta Kappa.